Document is current

Article History

Received: 10 October 2018

Revised: 28 January 2019

Accepted: 8 February 2019

First Online: 22 March 2019

Compliance with ethical standards

:

: The scientific guarantor of this publication is Catherine Oppenheim.

: The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

: One of the authors (GT) has significant statistical expertise.

: Written informed consent was obtained from all subjects (patients) or their legal representatives in the THRACE study.

: The THRACE study was approved by the CPP (Comité de Protection des Personnes) III Nord Est Ethics Committee and the research boards of the participating centers.

: In addition to the THRACE trial [1], the stroke population studied here has been published previously in the following articles dealing with entirely different scientific questions, respectively cost-effectiveness of thrombectomy in patients with acute ischemic stroke [2], impact of pretreatment lesional volume on clinical outcome and thrombectomy efficacy [3], outcome after reperfusion therapies in patients with large baseline DWI stroke lesions [4], susceptibility vessel sign [5, 6], inter- and intraobserver reliability for angiographic leptomeningeal collateral flow assessment by the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology scale [7], imaging features and safety and efficacy of endovascular stroke treatment [8] and Validation of Overestimation Ratio and TL-SVS as imaging biomarker of cardioembolic stroke and time from onset to MRI [9] whereas we focused on FLAIR vascular hyperintensities.1. Bracard S, Ducrocq X, Mas JL et al. (2016) Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomized controlled trial. Lancet Neurol 15(11):1138-1147.2. Achit H, Soudant M, Hosseini K et al. (2017) Cost-Effectiveness of Thrombectomy in Patients With Acute Ischemic Stroke: The THRACE Randomized Controlled Trial. Stroke 48(10):2843-2847.3. Xie Y, Oppenheim C, Guillemin F et al. (2018) Pretreatment lesional volume impacts clinical outcome and thrombectomy efficacy. Ann Neurol 83(1):178-185.4. Gautheron V, Xie Y, Tisserand M et al. (2018) Outcome after reperfusion therapies in patients with large baseline Diffusion-Weighted Imaging stroke lesions: a THRACE trial (mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke) subgroup analysis. Stroke 49(3):750-753.5. Bourcier R, Derraz I, Delasalle B et al. (2018) Susceptibility Vessel Sign and Cardioembolic Etiology in the THRACE Trial. Clin Neuroradiol.6. Bourcier R, Hassen WB, Soize S et al. (2018) Susceptibility vessel sign on MRI predicts better clinical outcome in patients with anterior circulation acute stroke treated with stent retriever as first-line strategy. J Neurointerv Surg.7. Ben Hassen W, Malley C, Boulouis G et al. (2018) Inter- and intraobserver reliability for angiographic leptomeningeal collateral flow assessment by the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) scale. J Neurointerv Surg.8. Roman LS, Menon BK, Blasco J et al. (2018) Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. Lancet Neurol 17(10):895-904.9.Bourcier R, Legrand L, Soize S et al. (in press) Clinical and MRI Technical Parameters Related to the Two Layered Susceptibility Vessel Sign and the Overestimation Ratio in the THRACE Trial. European Radiology.

: • Retrospective review of prospectively acquired data• Prognostic study/observational• Multicenter study